Correlation Between Hansa Biopharma and Oncopeptides

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hansa Biopharma and Oncopeptides at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hansa Biopharma and Oncopeptides into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hansa Biopharma AB and Oncopeptides AB, you can compare the effects of market volatilities on Hansa Biopharma and Oncopeptides and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hansa Biopharma with a short position of Oncopeptides. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hansa Biopharma and Oncopeptides.

Diversification Opportunities for Hansa Biopharma and Oncopeptides

0.73
  Correlation Coefficient

Poor diversification

The 3 months correlation between Hansa and Oncopeptides is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding Hansa Biopharma AB and Oncopeptides AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncopeptides AB and Hansa Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hansa Biopharma AB are associated (or correlated) with Oncopeptides. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncopeptides AB has no effect on the direction of Hansa Biopharma i.e., Hansa Biopharma and Oncopeptides go up and down completely randomly.

Pair Corralation between Hansa Biopharma and Oncopeptides

Assuming the 90 days trading horizon Hansa Biopharma AB is expected to generate 0.62 times more return on investment than Oncopeptides. However, Hansa Biopharma AB is 1.62 times less risky than Oncopeptides. It trades about -0.33 of its potential returns per unit of risk. Oncopeptides AB is currently generating about -0.23 per unit of risk. If you would invest  3,960  in Hansa Biopharma AB on August 25, 2024 and sell it today you would lose (892.00) from holding Hansa Biopharma AB or give up 22.53% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Hansa Biopharma AB  vs.  Oncopeptides AB

 Performance 
       Timeline  
Hansa Biopharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Oncopeptides AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Hansa Biopharma and Oncopeptides Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hansa Biopharma and Oncopeptides

The main advantage of trading using opposite Hansa Biopharma and Oncopeptides positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hansa Biopharma position performs unexpectedly, Oncopeptides can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncopeptides will offset losses from the drop in Oncopeptides' long position.
The idea behind Hansa Biopharma AB and Oncopeptides AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.